Generic Name and Formulations:
Cyclopentolate HCl 0.5%, 1%, 2%; oph soln; contains benzalkonium chloride.
Alcon Laboratories, Inc.
To produce mydriasis and cycloplegia.
Instill 1 or 2 drops of 0.5%, 1%, or 2% in the eye; may repeat in 5–10 minutes if necessary. Apply digital pressure to lacrimal sac for 2–3 minutes after instillation to reduce systemic absorption.
Small infants: instill 1 drop of 0.5% in the eye; apply pressure over nasolacrimal sac for 2–3 minutes, observe closely for 30 minutes. Children: instill 1 or 2 drops of 0.5%, 1%, or 2% in the eye; may repeat 5–10 minutes later with 0.5% or 1% solution if necessary; apply digital pressure to lacrimal sac for 2–3 minutes after instillation to reduce systemic absorption.
Untreated narrow-angle glaucoma or when untreated anatomically narrow angles are present.
Down's syndrome. Angle-closure glaucoma. Feeding intolerance in infants; withhold feeding for 4 hours after examination. Pregnancy (Cat.C). Nursing mothers.
May interfere with antihypertensive action of carbachol, pilocarpine, ophthalmic cholinesterase inhibitors.
Ocular effects (eg, increased intraocular pressure, burning, photophobia, blurred vision, irritation, hyperemia, conjunctivitis, blepharoconjunctivitis, punctate keratitis, synechiae); CNS disturbances (esp. in children).
Soln 0.5%—15mL; 1%, 2%—2mL, 5mL, 15mL
Join MIMS Learning now to manage all your CPD and notes in one place!
Already a MIMS Learning member?Sign In Now »
This red flags article explains signs and symptoms of potentially serious pathology in patients presenting...
This article by Dr Tillmann Jacobi covers the possible red flag symptoms to consider when a patient...
Dr Suneeta Kochhar provides an overview of red flag symptoms in patients presenting with headaches...
In this article, Dr David Brass and Dr Neil Rajan discuss the risk factors for BCC, making the diagnosis...
This article by Dr Rajiv Sankaranarayanan covers the diagnosis and management of cardiomyopathy. Key...
Dr Benjamin Simpson provides an in-depth overview of Parkinson’s disease, including information on risk...